APA (7th ed.) Citation

R, A., SK, A., R, A., AM, A., R, A., A, S., . . . MM, A. (2025). Electrospun Nanofiber-Scaffold-Loaded Levocetirizine Dihydrochloride Cerosomes for Combined Management of Atopic Dermatitis and Methicillin-Resistant Staphylococcus Aureus (MRSA) Skin Infection: In Vitro and In Vivo Studies. Pharmaceuticals (Basel, Switzerland), 18(5), . https://doi.org/10.3390/ph18050633

Chicago Style (17th ed.) Citation

R, Albash, Ali SK, Abdelmonem R, Agiba AM, Aldhahri R, Saleh A, Kassem AB, and Abdellatif MM. "Electrospun Nanofiber-Scaffold-Loaded Levocetirizine Dihydrochloride Cerosomes for Combined Management of Atopic Dermatitis and Methicillin-Resistant Staphylococcus Aureus (MRSA) Skin Infection: In Vitro and In Vivo Studies." Pharmaceuticals (Basel, Switzerland) 18, no. 5 (2025). https://doi.org/10.3390/ph18050633.

MLA (9th ed.) Citation

R, Albash, et al. "Electrospun Nanofiber-Scaffold-Loaded Levocetirizine Dihydrochloride Cerosomes for Combined Management of Atopic Dermatitis and Methicillin-Resistant Staphylococcus Aureus (MRSA) Skin Infection: In Vitro and In Vivo Studies." Pharmaceuticals (Basel, Switzerland), vol. 18, no. 5, 2025, https://doi.org/10.3390/ph18050633.